These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 8317910)

  • 1. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
    Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
    Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of serum tumour markers CEA, CA 50 and CA 242 in the distinction between malignant versus benign diseases causing jaundice and cholestasis; results from a prospective study.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(5):1687-93. PubMed ID: 1332581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
    Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1995; 15(6B):2731-7. PubMed ID: 8669855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
    Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
    Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
    Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
    Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT; Tao HQ; Zou SC
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of the value of imaging, serum markers and their combination in the diagnosis of pancreatic carcinoma in symptomatic patients.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Anticancer Res; 1992; 12(6B):2309-14. PubMed ID: 1295478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H; Kaya M; Cengiz A
    Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
    van Dalen A; Kessler AC
    Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
    Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
    Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P; Boadas J; González-Carro P; Mora J; Pérez C; Martínez A; Roca M; Lluís F; Farré A
    Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of serum tumour markers CEA, CA 50 and CA 242 in colorectal cancer.
    Eskelinen M; Pasanen P; Kulju A; Janatuinen E; Miettinen P; Poikolainen E; Tarvainen R; Nuutinen P; Pääkkönen M; Alhava E
    Anticancer Res; 1994; 14(3B):1427-32. PubMed ID: 8067718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
    Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
    Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receiver operating characteristic (ROC) curve analysis of the tumor markers CEA, CA 19-9 and CA 72-4 in gastric cancer.
    Fernández-Fernández L; Tejero E; Tieso A; Rabadán L; Munoz M; Santos I
    Int Surg; 1996; 81(4):400-2. PubMed ID: 9127805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
    Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
    Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.
    Gaspar MJ; De Miguel J; García Díaz JD; Díez M
    Anticancer Res; 2008; 28(5B):2947-52. PubMed ID: 19031938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.